- Home
- BHVN
BHVN
Biohaven Ltd.
as of 02-05-2026 3:58pm EST
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 1.1B | IPO Year: | 2017 |
| Target Price: | $30.36 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.48 - $44.28 | Next Earning Date: | 03-02-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -650274000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Biohaven Ltd. (BHVN)
VP, Chief Accounting Officer
Avg Cost/Share
$8.52
Shares
17,000
Total Value
$144,770.30
Owned After
20,000
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$7.50
Shares
666,666
Total Value
$4,999,995.00
Owned After
1,195,275
Director
Avg Cost/Share
$7.50
Shares
3,333,333
Total Value
$24,999,997.50
Owned After
5,653,904
SEC Form 4
Director
Avg Cost/Share
$7.50
Shares
400,000
Total Value
$3,000,000.00
Owned After
2,020,071
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Clark George C. | BHVN | VP, Chief Accounting Officer | Nov 17, 2025 | Buy | $8.52 | 17,000 | $144,770.30 | 20,000 | |
| Coric Vlad | BHVN | Chief Executive Officer | Nov 13, 2025 | Buy | $7.50 | 666,666 | $4,999,995.00 | 1,195,275 | |
| CHILDS JOHN W | BHVN | Director | Nov 13, 2025 | Buy | $7.50 | 3,333,333 | $24,999,997.50 | 5,653,904 | |
| Bailey Gregory | BHVN | Director | Nov 13, 2025 | Buy | $7.50 | 400,000 | $3,000,000.00 | 2,020,071 |
Compare BHVN vs Leading Stocks
See how BHVN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BHVN Biohaven Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.